CD8A and neoplasm: In summary, these findings suggest that C5‐PE38 treatment triggers a STING‐mediated type I IFN response in APCs via released nucleic acids, potentially reshaping the tumor microenvironment and eliciting CD8+ T cell‐mediated antitumor immunity (Figure 6j).